Enterome products
Enterome - Therapeutic Cancer Vaccines
OncoMimicsTM vaccines are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid tumors, respectively.
Enterome - First-In-Class, Orally Administered Small Molecule
Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream.
Enterome - New Generation Of Oral Bioactives
New generation of oral bioactives to treat inflammatory and autoimmune diseases. EndoMimicsTM are first-in-class orally available bioactives drugs based on proteins secreted by the gut bacteria that act like human hormones or cytokines. Enterome expects partnering to play a central in generating value from its EndoMimics pipeline.
Bioactives
Enterome - IBD, Food Allergy
EB1010 is an orally administered, GI-selective next generation IL-10 inducer designed to induce high local secretion of IL-10 for the treatment of Inflammatory Bowel Disease (IBD) and food allergy. EB1010 is a peptide that modulates the immune system by closely mimicking effects of a specific class of hormones. IL-10 deficiency is central to auto-immune, inflammatory and allergic diseases and a major opportunity exists for an IL-10 inducer that can overcome the limitations of earlier recombinant IL-10 candidates, such as poor stability and tolerability and high systemic dose with limited local exposure. EB1010 is due to enter the clinic in 2023.
Technology- Programs & Products - Immuno-Oncology
Enterome - B-Cell Malignancies Drug
EO2463 comprises OncoMimics that are highly expressed on B-cell malignancies.